HealthWarehouse AI Stock Analysis
Want to see HEWA full AI Analyst Report?
HealthWarehouse (HEWA) AI Stock Analysis
HealthWarehouse
(Other OTC:HEWA)
HEWA scores at the low end of the range, driven primarily by a structurally impaired balance sheet: stockholders' equity is negative at roughly -$4.1 million, with $3.5 million of debt against just $4.6 million of assets, leaving no cushion and a likely need for dilutive financing or restructuring. Compounding this, the business has swung back to losses and roughly $2.3 million of cash burn after a brief profitable year in 2025, with TTM revenue down 6.2%. Technicals reinforce the caution, as the stock trades below all key moving averages in a sustained downtrend, while valuation provides no offset given negative earnings and no dividend. Genuine positives — a gross margin rebound to about 49%, minimal capital spending, and a demonstrated ability to generate cash when profitable — are not sufficient to outweigh the solvency and liquidity risks. Earnings call and corporate event components were excluded for lack of data, with their weight redistributed proportionally.
HealthWarehouse (HEWA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.11M
- Dividend Yield
- ―
- Average Volume (3M)
- 33.03K
- Price to Earnings (P/E)
- -2.8
- Beta (1Y)
- -0.15
- Revenue Growth
- -45.46%
- EPS Growth
- -881.25%
- Country
- US
- Employees
- 121
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
HealthWarehouse Business Overview & Revenue Model
Company Description
HealthWarehouse.com, Inc. functions as a digital and direct-mail pharmaceutical service. Its offerings encompass a broad spectrum of pharmaceutical items, including generic and brand-name prescription drugs, specialized medications for pets, and a va...
HealthWarehouse Financial Statement Overview
Summary
Financial strength is weak across all three statements. The balance sheet is the primary concern, with persistently negative stockholders' equity of about -$4.1 million, $3.5 million of debt against only $4.6 million of total assets, and no equity cushion to absorb shocks. Cash flow has swung sharply negative, with roughly -$2.3 million of operating and free cash flow in the trailing-twelve-month period versus +$1.1 million free cash flow in 2025, a material burn relative to the company's small asset base. The income statement is the relative bright spot: revenue grew strongly through 2024-2025 and the company briefly reached profitability in 2025, while gross margin has recovered to about 49%. However, TTM revenue has fallen 6.2% to $28.8 million and the company has swung back to a $1.1 million net loss, leaving five losses in the last six reported periods and no durable profitability.
Income Statement
36NegativeBalance Sheet
12Very NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.82M | 48.99M | 33.61M | 20.28M | 18.14M | 16.14M |
| Gross Profit | 14.07M | 17.14M | 13.69M | 12.17M | 11.94M | 11.13M |
| EBITDA | -434.69K | 931.62K | 338.42K | -1.28M | -559.33K | -224.76K |
| Net Income | -1.08M | 265.00K | -332.97K | -1.77M | -952.03K | -572.50K |
Balance Sheet | ||||||
| Total Assets | 4.57M | 5.88M | 5.05M | 3.21M | 3.97M | 3.62M |
| Cash, Cash Equivalents and Short-Term Investments | 755.09K | 2.21M | 1.13M | 567.96K | 1.04M | 2.18M |
| Total Debt | 3.50M | 2.90M | 3.84M | 2.09M | 3.04M | 2.15M |
| Total Liabilities | 8.70M | 9.18M | 9.08M | 7.21M | 7.00M | 6.41M |
| Stockholders Equity | -4.13M | -3.30M | -4.04M | -4.01M | -3.03M | -2.79M |
Cash Flow | ||||||
| Free Cash Flow | -2.28M | 1.06M | 565.36K | -473.81K | -1.14M | 313.64K |
| Operating Cash Flow | -2.25M | 1.16M | 705.26K | -163.84K | -624.45K | 400.51K |
| Investing Cash Flow | -27.26K | -95.23K | -139.90K | -309.97K | -512.85K | -86.86K |
| Financing Cash Flow | 0 | 9,000 | 0 | 0 | 0 | 0 |
HealthWarehouse Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HEWA, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 32.44 is Neutral, neither overbought nor oversold. The STOCH value of 10.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HEWA.
HealthWarehouse Peers Comparison
Overall Rating
HSCS45Neutral
NDRA42Neutral
PETS41Neutral
LFMD39Underperform
HEWA32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $10.24M | -0.66 | -816.25% | ― | -27.70% | 61.44% | |
| 42Neutral | $5.88M | -0.77 | -150.38% | ― | ― | 60.87% | |
| 41Neutral | $20.04M | -0.70 | -107.10% | ― | -17.81% | 51.57% | |
| 39Underperform | $82.17M | -3.28 | -192.39% | ― | -25.13% | -208.75% | |
| 32Underperform | $4.22M | -2.80 | 28.93% | ― | -45.46% | -881.25% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HEWA | HealthWarehousecom | 0.07 | -0.06 | -43.85% | |
| PETS | Petmed Express | 0.90 | -0.70 | -43.86% | |
| NDRA | Endra Life Sciences | 4.04 | -1.60 | -28.46% | |
| LFMD | Lifemd, Inc. | 1.70 | -2.01 | -54.18% | |
| KTTA | Pasithea Therapeutics Corp. | 0.51 | 0.09 | 21.43% | |
| HSCS | Heart Test Laboratories, Inc. | 2.10 | -0.81 | -27.84% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 15, 2026
